Inarigivir

Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a RIG-I agonist to activate cellular innate immune responses[1][2].

Product Specifications

CAS Number

[475650-36-3]

Product Name Alternative

ORI-9020; SB-9000

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Inarigivir.html

Purity

99.20

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

NC1=C(N=CN2[C@@H]3O[C@H](COP(O[C@H]4[C@@H](OC)[C@H](N5C=CC(NC5=O)=O)O[C@@H]4CO)(S)=O)[C@@H](O)C3)C2=NC=N1

Molecular Formula

C20H26N7O10PS

Molecular Weight

587.50

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48 (6) :2318-20.|[2]Danni Colledge, et al. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos (t) ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro.